Atrial cardiomyopathy: new pathophysiological and clinical aspects

Atrial cardiomyopathy (ACM) is increasingly recognized as a key contributor to the development and perpetuation of atrial fibrillation (AF), a prevalent cardiac arrhythmia with significant clinical implications. ACM involves complex structural, electrical, and functional remodeling of the atrial myocardium, driven by various pathological conditions such as hypertension, heart failure, and obesity. Key mechanisms include atrial fibrosis, inflammation, and oxidative stress, which collectively contribute to the pro-arrhythmic and pro-thrombotic state associated with AF. Recent studies highlight the role of epicardial adipose tissue in promoting atrial fibrosis and the importance of genetic predispositions in ACM development. Advanced imaging techniques, including left atrial strain and cardiac magnetic resonance, are emerging as valuable tools for assessing atrial remodeling and guiding therapeutic decisions. Understanding the intricate relationship between ACM and AF may enable earlier identification and targeted interventions, potentially improving outcomes in affected patients. Despite advances, gaps remain in identifying early markers of ACM and developing specific therapeutic strategies. This review focuses on the analysis of ACM as a contributor to AF and its pathophysiological and clinical implications. Future research should focus on refining diagnostic criteria and exploring novel treatment approaches to manage ACM and its associated risks more effectively.